| Literature DB >> 26202953 |
Deepak Raj1, Alexandra Aicher1, Christopher Heeschen1.
Abstract
Pancreatic cancer stem cells (CSCs) have been first described in 2007 and since then have emerged as an intriguing entity of cancer cells with distinct functional features including self-renewal and exclusive in vivo tumorigenicity. The heterogeneous pancreatic CSC pool has been implicated in tumor propagation as well as metastatic spread. Clinically, the most important feature of CSCs is their strong resistance to standard chemotherapy, which results in fast disease relapse, even with today's more advanced chemotherapeutic regimens. Therefore, novel therapeutic strategies to most efficiently target pancreatic CSCs are being developed and their careful clinical translation should provide new avenues to eradicate this deadly disease.Entities:
Keywords: Cancer stem cells; Pancreatic ductal adenocarcinoma; Stromal cells; Therapeutics/intervention
Mesh:
Year: 2015 PMID: 26202953 DOI: 10.1002/stem.2114
Source DB: PubMed Journal: Stem Cells ISSN: 1066-5099 Impact factor: 6.277